Market Cap 5.26B
Revenue (ttm) 290.52M
Net Income (ttm) 89.16M
EPS (ttm) N/A
PE Ratio 36.51
Forward PE 38.01
Profit Margin 30.69%
Debt to Equity Ratio 0.00
Volume 397,400
Avg Vol 378,266
Day's Range N/A - N/A
Shares Out 28.94M
Stochastic %K 99%
Beta 0.64
Analysts Strong Sell
Price Target $207.30

Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treati...

Industry: Biotechnology
Sector: Healthcare
Phone: 412 586 5830
Address:
2100 Wharton Street, Suite 701, Pittsburgh, United States
Ortho91
Ortho91 Oct. 4 at 1:50 AM
$KRYS looks great from buying more at lows. Now we are 183. Going to 225 by December or more
0 · Reply
VAK7
VAK7 Oct. 1 at 8:41 PM
1 · Reply
highnihilism
highnihilism Sep. 30 at 10:11 AM
$IJR iShares Core S&P Small-Cap: 54 trades, $56K vs $122K avg (0.46x). $38K calls / $17K puts. $PAGS Pagseguro Digital: 115 trades, $41K vs $102K avg (0.40x). $38K calls / $3K puts. $KRYS Krystal Biotech: 58 trades, $67K vs $171K avg (0.39x). $38K calls / $30K puts. $GAU Galiano Gold: 83 trades, $41K vs $15K avg (2.65x). $38K calls / $3K puts.
0 · Reply
MaverikIT
MaverikIT Sep. 29 at 5:36 PM
0 · Reply
AJALMOSAWY
AJALMOSAWY Sep. 29 at 3:27 PM
0 · Reply
projectmechadoge
projectmechadoge Sep. 26 at 4:39 AM
$KRYS grok just told me to buy this , no position
0 · Reply
Fugazi_
Fugazi_ Sep. 24 at 9:25 PM
$KRYS Never seen 1.8k volume, and then the next day it dissapears, no OI or anything. Very odd
0 · Reply
ZManicItalian
ZManicItalian Sep. 22 at 2:05 PM
$KRYS going $200+ in 2026 if not by the end of this year
0 · Reply
aaxaa
aaxaa Sep. 19 at 2:29 PM
0 · Reply
enriquesaaa
enriquesaaa Sep. 18 at 7:53 PM
$KRYS squeeze baby squeeze
0 · Reply
Latest News on KRYS
Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 12:42 PM EDT - 2 months ago

Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript


Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript

May 6, 2025, 2:43 PM EDT - 5 months ago

Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript


Krystal Biotech to Present at Upcoming Scientific Conferences

Apr 24, 2025, 8:00 AM EDT - 5 months ago

Krystal Biotech to Present at Upcoming Scientific Conferences


Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Apr 7, 2025, 4:30 PM EDT - 6 months ago

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer


Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 11:43 AM EST - 8 months ago

Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript


Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy

Dec 27, 2024, 8:30 AM EST - 10 months ago

Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy


Krystal Biotech to Present at Upcoming Investor Conferences

Nov 27, 2024, 7:00 AM EST - 11 months ago

Krystal Biotech to Present at Upcoming Investor Conferences


Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 3:31 PM EST - 11 months ago

Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript


Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript

May 6, 2024, 11:44 AM EDT - 1 year ago

Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript


Krystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 11:47 AM EST - 1 year ago

Krystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call Transcript


Ortho91
Ortho91 Oct. 4 at 1:50 AM
$KRYS looks great from buying more at lows. Now we are 183. Going to 225 by December or more
0 · Reply
VAK7
VAK7 Oct. 1 at 8:41 PM
1 · Reply
highnihilism
highnihilism Sep. 30 at 10:11 AM
$IJR iShares Core S&P Small-Cap: 54 trades, $56K vs $122K avg (0.46x). $38K calls / $17K puts. $PAGS Pagseguro Digital: 115 trades, $41K vs $102K avg (0.40x). $38K calls / $3K puts. $KRYS Krystal Biotech: 58 trades, $67K vs $171K avg (0.39x). $38K calls / $30K puts. $GAU Galiano Gold: 83 trades, $41K vs $15K avg (2.65x). $38K calls / $3K puts.
0 · Reply
MaverikIT
MaverikIT Sep. 29 at 5:36 PM
0 · Reply
AJALMOSAWY
AJALMOSAWY Sep. 29 at 3:27 PM
0 · Reply
projectmechadoge
projectmechadoge Sep. 26 at 4:39 AM
$KRYS grok just told me to buy this , no position
0 · Reply
Fugazi_
Fugazi_ Sep. 24 at 9:25 PM
$KRYS Never seen 1.8k volume, and then the next day it dissapears, no OI or anything. Very odd
0 · Reply
ZManicItalian
ZManicItalian Sep. 22 at 2:05 PM
$KRYS going $200+ in 2026 if not by the end of this year
0 · Reply
aaxaa
aaxaa Sep. 19 at 2:29 PM
0 · Reply
enriquesaaa
enriquesaaa Sep. 18 at 7:53 PM
$KRYS squeeze baby squeeze
0 · Reply
enriquesaaa
enriquesaaa Sep. 18 at 7:53 PM
$KRYS My gosh, sitting at 160$ 🤩🤩🤩
0 · Reply
ZManicItalian
ZManicItalian Sep. 18 at 4:29 PM
$KRYS bust through $160. Do that damn thing!
0 · Reply
alexpitti
alexpitti Sep. 16 at 11:42 PM
$KRYS investors can scream about the competitive landscape and act like they are right about what patients will choose because $ABEO has fallen recently, but of course competition has nothing to do with manufacturing. Abeona needs to actually produce the sheets and put them on patients before we see how the landscape develops. The demand is there, hospitals want it, and insurers are reimbursing it. The question right now is manufacturing and the results over time of the product.
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 5:23 PM
$KRYS just got a major catalyst 🚀 FDA expanded Vyjuvek’s label to cover DEB patients from birth, plus at-home use flexibility — a big win fueling today’s rally. Full breakdown of the move here 👉 https://www.zacks.com/stock/news/2752364/krystal-biotech-stock-up-on-fda-nod-to-vyjuvek-label-update?cid=sm-stocktwits-2-2752364-teaser-12720&ADID=SYND_STOCKTWITS_TWEET_2_2752364_TEASER_12720
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 4:23 PM
$KRYS jumps 8.4% on FDA label update for Vyjuvek 🚀 This allows DEB treatment from birth and at-home administration, increasing convenience and potential future sales. With recent approvals in Europe and Japan, Vyjuvek is set for expansion with planned launches in Germany and France in 2025. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2752364/krystal-biotech-stock-up-on-fda-nod-to-vyjuvek-label-update?cid=sm-stocktwits-2-2752364-body-12699&ADID=SYND_STOCKTWITS_TWEET_2_2752364_BODY_12699
0 · Reply
highnihilism
highnihilism Sep. 16 at 3:03 PM
Biotech → $KRYS Krystal Biotech $NTRA Natera $MYGN Myriad Genetics $VIR Vir Biotechnology $TWST Twist Bioscience
0 · Reply
highnihilism
highnihilism Sep. 16 at 3:00 PM
Biotech → $SPRY Ars Pharmaceuticals $CPRX Catalyst Pharmaceuticals $KRYS Krystal Biotech $NTRA Natera $MYGN Myriad Genetics
0 · Reply
ZManicItalian
ZManicItalian Sep. 15 at 9:33 PM
$KRYS news might help it to finally break loose to $200+ 🤑
0 · Reply
enriquesaaa
enriquesaaa Sep. 15 at 7:48 PM
Huge day for $KRYS Congrats to all those who held the last days shake out. We could see 200 in a few weeks.
1 · Reply
JarvisFlow
JarvisFlow Sep. 15 at 6:32 PM
HC Wainwright & Co. has adjusted their stance on Krystal Biotech ( $KRYS ), setting the rating to Buy with a target price of 240.
0 · Reply
prismmarketview
prismmarketview Sep. 15 at 1:49 PM
(NASDAQ: $KRYS) @KrystalBiotech wins FDA nod for an expanded VYJUVEK label—now approved from birth & for at-home caregiver use. A major step for rare disease access & a boost to KRYS’s growth outlook. https://prismmarketview.com/krystal-biotech-secures-fda-approval-for-expanded-vyjuvek-label-extending-access-and-usability/
0 · Reply
enriquesaaa
enriquesaaa Sep. 10 at 3:27 PM
$KRYS does anyone know the reason behind the fall these past days?
1 · Reply